[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sinovac (Dalian) Vaccine Technology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,65,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100629342","phase-3-immunogenicity-and-safety-of-varicella-vaccine-live-in-healthy-vietnamese-children-100629342",false,"NCT07473427","Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children","Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","Inclusion Criteria:\n\n1. Healthy children aged 1-12 years;\n2. Vaccination history:\n\n   * Participants aged 1 year old: no vaccination history with any varicella containing vaccine;\n   * Participants aged 2\\~12 years old: no vaccination history with any varicella containing vaccine, or have received 1 dose of varicella vaccine at least 3 months before enrollment;\n3. Participants and\u002For their legal guardians are able to understand and sign the informed consent\u002Fassent voluntarily;\n4. Participants are able to comply with the study procedures based on the assessment of the investigator;\n5. Participants should provide verifiable identification, to be contacted, and to contact the investigator during the study period.\n\nExclusion Criteria:\n\n1. Prior history of VZV infection;\n2. Have been exposed to VZV at home, day care, school, etc. within 4 weeks before enrollment;\n3. Known allergy to vaccines or vaccine ingredients, or serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;\n4. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n5. Coagulation disorders (e.g. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n6. Poorly controlled chronic illnesses or history of severe diseases that, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, and a history of major organ transplantation;\n7. Any confirmed or suspected syphilis, hepatitis B or hepatitis C infection;\n8. Current or history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n9. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥20mg\u002Fday, or prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment during the trial;\n10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the trial;\n11. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n12. Receipt of attenuated live vaccines or nucleic acid vaccines within 28 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n13. Fever on vaccination day, with axillary temperature \\>37.2°C pre-vaccination, or vital signs outside normal range, or failure to pass physical examination;\n14. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with drug administration or observation of local reactions;\n15. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n16. Any other factors considered by the investigator to make the participant unsuitable for participation in the trial.",true,"ALL","1 Year","12 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled. All participants will receive a single dose of varicella vaccine manufactured by Sinovac.",[28,29],"Varicella (Chickenpox)","Varicella Immunisation","NOT_YET_RECRUITING","2026-06-10",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":22},"2026-06-15",{"date":38,"type":22},"2026-10-01",{"name":40,"class":41},"Sinovac (Dalian) Vaccine Technology Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100629463","phase-3-second-dose-of-varicella-vaccine-in-healthy-children-100629463","NCT07475000","Second Dose of Varicella Vaccine in Healthy Children","Immunogenicity and Safety of the Second Dose of Varicella Vaccine in Healthy Children: An Open-label Study","Inclusion Criteria:\n\n1. Healthy children aged 15 months to 12 years.\n2. Have received one dose of varicella vaccine at 12 months of age in Turkey (verified by vaccination card or official electronic immunization record).\n3. Written informed consent obtained from parent(s) or legally authorized representative(s); assent obtained from children as applicable according to local regulations.\n4. Able to comply with study procedures, as assessed by the investigator.\n5. Able to provide verifiable identification and be contacted for study follow-up during the study period.\n\nExclusion Criteria:\n\n1. History of varicella-zoster virus (VZV) infection (based on parental report or medical record).\n2. Known exposure to VZV within 4 weeks prior to screening.\n3. Receipt of more than one dose of varicella vaccine.\n4. Interval between first dose of varicella vaccine and enrollment less than 3 months.\n5. Known allergy to any vaccine component or history of severe allergic reaction to any vaccine (e.g., urticaria, dyspnea, angioedema).\n6. Known or suspected immunodeficiency or autoimmune disease (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, or HIV infection).\n7. Poorly controlled chronic disease or history of severe systemic disease.\n8. Current or history of severe neurological disorders (e.g., epilepsy, convulsions or seizures excluding simple febrile seizures) or psychiatric disorders.\n9. Receipt of ≥14 days of immunosuppressive or immunomodulatory therapy (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday or equivalent), or cytotoxic therapy within 180 days prior to screening, or planned use during the study period.\n10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or planned receipt during the study period.\n11. Receipt of other investigational drugs or vaccines within 30 days prior to screening, or planned receipt during the study period.\n12. Receipt of live attenuated or nucleic acid vaccines within 28 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening.\n13. Fever (axillary temperature \\>37.2°C), abnormal vital signs, or clinically significant abnormal findings on physical examination on the day of vaccination.\n14. Skin conditions at the intended injection site (e.g., inflammation, ulceration, rash, scar, or other conditions that may interfere with administration or safety assessment).\n15. Acute illness or exacerbation of chronic disease within 7 days prior to vaccination, or known or suspected active infection.\n16. Any condition that, in the opinion of the investigator, would make the participant unsuitable for participation in the study.","15 Months",{"count":21,"type":22},[25],"This study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled. Written informed consent form will be obtained from participants' parents or legally acceptable representatives (and assents will be obtained from participants aged above 9 years old and written consent forms will be prepared and consent will be obtained in writing if possible from the participants aged 3-8 years old.) before enrollment. Participants will be assigned to 5 groups according to the brand of first dose varicella vaccine they received at the age of 12 months. All participants will receive the second dose of varicella vaccine manufactured by Sinovac.\n\nThe duration of individual participation from enrollment to the last onsite visit will be a maximum of 42 days. The end of study is considered the completion of the last visit for the last participant in this study.\n\nBlood samples (2.5 - 3.0ml per time) for immunogenicity assessment will be collected. The blood samples will be collected before vaccination and 42 days after vaccination.",[28,29],"RECRUITING","2026-03-11",{"date":58,"type":34},"2026-03-16",{"date":60,"type":34},"2026-01-28",{"date":62,"type":22},"2026-11-15",{"name":40,"class":41},5,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":42},"100584632","phase-4-study-of-live-attenuated-varicella-vaccine-co-administered-with-mmr-vaccine-or-dtap-vaccine-100584632","NCT06891872","Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","Immunogenicity and Safety of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine in Healthy Children Aged 18~24 Months: an Open-label, Randomized, Phase Ⅳ Study Clinical Trial","Inclusion Criteria:\n\n* Infants aged 18-24 months;\n* have completed 3 doses of DTaP for primary immunization in their first year of life without the fourth dose of Dtap-containing vaccine;\n* have completed the first dose of MMR in their first year of life without a second dose of MMR;\n* Guardians of participants who are able to understand and voluntarily sign informed consent;\n* Provision of legal proof of identity.\n\nExclusion Criteria:\n\n* Having a history of previous varicella vaccination;\n* Having a history of chickenpox, pertussis, diphtheria, tetanus, measles, mumps, and rubella;\n* Having a history of uncontrolled chronic or serious diseases, including but not limited to cardiovascular diseases, hematological diseases, liver and kidney diseases, digestive diseases, respiratory diseases, malignant tumors, major functional organ transplantation, etc.;\n* Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n* Presence of abnormal coagulation function (e.g. coagulation factor deficiency, platelet abnormality);\n* Having\u002FPrevious having a severe neurological disorder (epilepsy, seizures, or convulsions) or psychosis, or have a family history of psychosis;\n* Acute onset of various acute or chronic illnesses within the last 7 days, or known or suspected active infection;\n* Receipt of \\> 14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2 mg\u002Fkg\u002F day or its equivalent, except topical or inhaled corticosteroids), cytotoxic therapy within the past 6 months, or planned to receive such therapy during the trial;\n* Having received immune globulin or other blood products within the past 3 months or plan to receive such treatment during the trial;\n* Receipt of another study drug or vaccine within the past 30 days or plans to receive such drug or vaccine during the trial;\n* Administration of live attenuated vaccine within the past 28 days or subunit, inactivated, or other process vaccine within the past 7 days;\n* Known allergies to the vaccine or vaccine components, such as urticaria after vaccination, dyspnea, angioedema;\n* Having fever on the day of scheduled vaccination (axillary temperature \\> 37.0 ° C);\n* Failure of medical examination on the planned vaccination day;\n* Participants have any other factors that, in the judgment of the investigator, make them ineligible to participate in a clinical trial.","18 Months","24 Months",{"count":75,"type":22},720,[77],"PHASE4","This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.",[80,81,82],"Varicella (chickenpox)","MMR Vaccine","DTaP Vaccine",[84,85],"Co-administered","VZV","2025-03-17",{"date":88,"type":34},"2025-03-24",{"date":90,"type":22},"2025-05",{"date":92,"type":22},"2025-12",{"name":40,"class":41},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100553140","correlation-of-protection-against-varicella-in-an-exploratory-study-100553140","NCT06482216","Correlation of Protection Against Varicella in an Exploratory Study","Inclusion Criteria:\n\n* 1-12 years children who were the siblings or children of the indicator varicella cases, or the deskmates\u002Froommates of the indicator varicella cases;\n* Having close contacts with the indicator varicella cases at least 2 days during the period from 5 days before the onset and 2 days after the onset;\n* Without varicella vaccination history or having varicella vaccination history (the last dose of varicella was manufacured by Sinovac, with an interval of \\>30 days before enrollment)\n* Subjects\u002Flegal guardian can understand and sign the informed consent;\n* Being able to provide legal proof of identity.\n\nExclusion Criteria:\n\n* Without varicella history;\n* Body temperature ≥37.0℃ on the day of enrollment, or skin rash on the head, torso, and limbs;\n* Having any confirmed or suspected immunodeficiency disorder, including tumor patients undergoing chemotherapy, human immunodeficiency virus (HIV) infection, continuous use of steroid hormones for more than 30 days (prednisone equivalent ≥2mg\u002Fkg days in children), or having other immunosuppressive disorder as determined by the clinician;\n* The investigators considered that participation in this study was not appropriate for various other reasons.",{"count":101,"type":22},400,"OBSERVATIONAL","This study consists of two parts. Part 1 is a retrospective cohort study and part 2 is a prospective cohort study. In Part 1 ,the scaled logit model was used to assess the correlation between varicella-zoster virus (VZV) antibody titers using fluorescent-antibody-to-membrane-antigen assay (FAMA) 30 days after varicella vaccine immunization and the risk of subsequent varicella breakout\u002Fdisease , to determine the protective threshold for achieving FAMA antibodies. Part 2 was to validate the model in part 1.",[105],"Varicella","2025-01-23",{"date":108,"type":34},"2025-01-27",{"date":110,"type":22},"2025-10-10",{"date":112,"type":22},"2028-10-10",{"name":40,"class":41},""]